Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan
- Written by PR Newswire
![]() |
- Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan Food and Drug Administration
- Lunit's latest commercial approval to accelerate expansion in the Taiwanese market
SEOUL, South Korea, Aug. 25, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a leading medical AI provider, today announced that it received...
Read more: Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan















